Aigen Investment Management LP Has $274,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Aigen Investment Management LP lowered its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 25.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,794 shares of the company’s stock after selling 1,990 shares during the period. Aigen Investment Management LP’s holdings in Kymera Therapeutics were worth $274,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in KYMR. Price T Rowe Associates Inc. MD raised its position in Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after acquiring an additional 996,300 shares during the period. Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 19.2% during the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after buying an additional 769,486 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Kymera Therapeutics by 3.0% in the first quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock valued at $156,333,000 after purchasing an additional 113,888 shares during the last quarter. Artal Group S.A. grew its stake in shares of Kymera Therapeutics by 19.6% in the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after purchasing an additional 496,400 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Kymera Therapeutics by 2.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company’s stock worth $12,115,000 after purchasing an additional 10,731 shares during the period.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $41.96 on Friday. The firm has a market cap of $2.72 billion, a PE ratio of -17.93 and a beta of 2.21. The firm’s 50 day simple moving average is $47.17 and its 200-day simple moving average is $41.62. Kymera Therapeutics, Inc. has a one year low of $16.94 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. During the same period last year, the company posted ($0.90) earnings per share. Equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on KYMR shares. Oppenheimer boosted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Morgan Stanley lifted their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Truist Financial reaffirmed a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Finally, Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research note on Monday, August 26th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.21.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.